Fusion Proteins, bcr-abl/metabolism; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology; Antineoplastic Agents/administration & dosage; Antineoplastic Agents/pharmacology; Antineoplastic Agents/therapeutic use; Benzamides; Biomarkers, Tumor; Blast Crisis/enzymology; Disease Management; Disease Progression; Drug Administration Schedule; Drug Monitoring; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl/genetics; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/enzymology; Leukemia, Myeloid, Chronic-Phase/drug therapy; Leukemia, Myeloid, Chronic-Phase/enzymology; Leukemia, Myeloid, Chronic-Phase/pathology; Medication Adherence; Piperazines/administration & dosage; Piperazines/pharmacology; Piperazines/therapeutic use; Protein Kinase Inhibitors/administration & dosage; Protein Kinase Inhibitors/pharmacology; Protein Kinase Inhibitors/therapeutic use; Pyrimidines/administration & dosage; Pyrimidines/pharmacology; Pyrimidines/therapeutic use; RNA, Messenger/biosynthesis; RNA, Messenger/genetics; RNA, Neoplasm/biosynthesis; RNA, Neoplasm/genetics; Randomized Controlled Trials as Topic/statistics & numerical data; Recurrence; Retrospective Studies; Time Factors